nodes	percent_of_prediction	percent_of_DWPC	metapath
Arformoterol—ADRB2—polycystic ovary syndrome	0.756	1	CbGaD
Arformoterol—Tonsillitis—Metformin—polycystic ovary syndrome	0.0106	0.127	CcSEcCtD
Arformoterol—Viral diarrhoea—Metformin—polycystic ovary syndrome	0.0102	0.123	CcSEcCtD
Arformoterol—Tooth abscess—Metformin—polycystic ovary syndrome	0.00639	0.077	CcSEcCtD
Arformoterol—Fenoterol—ADRB3—polycystic ovary syndrome	0.00223	0.183	CrCbGaD
Arformoterol—Nasal congestion—Metformin—polycystic ovary syndrome	0.00213	0.0256	CcSEcCtD
Arformoterol—Injury—Metformin—polycystic ovary syndrome	0.00211	0.0254	CcSEcCtD
Arformoterol—Arbutamine—ADRB3—polycystic ovary syndrome	0.00208	0.171	CrCbGaD
Arformoterol—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00198	0.0239	CcSEcCtD
Arformoterol—Dehydration—Metformin—polycystic ovary syndrome	0.0018	0.0217	CcSEcCtD
Arformoterol—Cramp muscle—Metformin—polycystic ovary syndrome	0.00174	0.021	CcSEcCtD
Arformoterol—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00173	0.0209	CcSEcCtD
Arformoterol—Influenza—Metformin—polycystic ovary syndrome	0.00167	0.0202	CcSEcCtD
Arformoterol—Angina pectoris—Metformin—polycystic ovary syndrome	0.00163	0.0196	CcSEcCtD
Arformoterol—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00156	0.0187	CcSEcCtD
Arformoterol—Labetalol—ADRB3—polycystic ovary syndrome	0.00148	0.121	CrCbGaD
Arformoterol—Rhinitis—Metformin—polycystic ovary syndrome	0.00134	0.0162	CcSEcCtD
Arformoterol—Oedema peripheral—Metformin—polycystic ovary syndrome	0.00132	0.0159	CcSEcCtD
Arformoterol—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00132	0.0159	CcSEcCtD
Arformoterol—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00124	0.015	CcSEcCtD
Arformoterol—Immune system disorder—Metformin—polycystic ovary syndrome	0.00121	0.0146	CcSEcCtD
Arformoterol—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00121	0.0146	CcSEcCtD
Arformoterol—Malnutrition—Metformin—polycystic ovary syndrome	0.00117	0.0141	CcSEcCtD
Arformoterol—Dysgeusia—Metformin—polycystic ovary syndrome	0.00114	0.0138	CcSEcCtD
Arformoterol—Muscle spasms—Metformin—polycystic ovary syndrome	0.00112	0.0135	CcSEcCtD
Arformoterol—Tremor—Metformin—polycystic ovary syndrome	0.00109	0.0132	CcSEcCtD
Arformoterol—Isoprenaline—ADRB3—polycystic ovary syndrome	0.00109	0.0892	CrCbGaD
Arformoterol—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.00108	0.013	CcSEcCtD
Arformoterol—Malaise—Metformin—polycystic ovary syndrome	0.00105	0.0127	CcSEcCtD
Arformoterol—Palpitations—Metformin—polycystic ovary syndrome	0.00103	0.0124	CcSEcCtD
Arformoterol—Hypertension—Metformin—polycystic ovary syndrome	0.00101	0.0121	CcSEcCtD
Arformoterol—Myalgia—Metformin—polycystic ovary syndrome	0.000993	0.012	CcSEcCtD
Arformoterol—Chest pain—Metformin—polycystic ovary syndrome	0.000993	0.012	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000986	0.0119	CcSEcCtD
Arformoterol—Discomfort—Metformin—polycystic ovary syndrome	0.000981	0.0118	CcSEcCtD
Arformoterol—Oedema—Metformin—polycystic ovary syndrome	0.000952	0.0115	CcSEcCtD
Arformoterol—Infection—Metformin—polycystic ovary syndrome	0.000945	0.0114	CcSEcCtD
Arformoterol—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000933	0.0112	CcSEcCtD
Arformoterol—Skin disorder—Metformin—polycystic ovary syndrome	0.000924	0.0111	CcSEcCtD
Arformoterol—Hypotension—Metformin—polycystic ovary syndrome	0.000889	0.0107	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000867	0.0105	CcSEcCtD
Arformoterol—Dyspnoea—Metformin—polycystic ovary syndrome	0.000848	0.0102	CcSEcCtD
Arformoterol—Fenoterol—ADRB2—polycystic ovary syndrome	0.000847	0.0695	CrCbGaD
Arformoterol—Ritodrine—ADRB2—polycystic ovary syndrome	0.000847	0.0695	CrCbGaD
Arformoterol—Somnolence—Metformin—polycystic ovary syndrome	0.000846	0.0102	CcSEcCtD
Arformoterol—Dyspepsia—Metformin—polycystic ovary syndrome	0.000838	0.0101	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000822	0.0099	CcSEcCtD
Arformoterol—Fatigue—Metformin—polycystic ovary syndrome	0.00082	0.00989	CcSEcCtD
Arformoterol—Constipation—Metformin—polycystic ovary syndrome	0.000814	0.00981	CcSEcCtD
Arformoterol—Arbutamine—ADRB2—polycystic ovary syndrome	0.000793	0.065	CrCbGaD
Arformoterol—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000784	0.00945	CcSEcCtD
Arformoterol—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000778	0.00938	CcSEcCtD
Arformoterol—Formoterol—ADRB2—polycystic ovary syndrome	0.000769	0.0631	CrCbGaD
Arformoterol—Urticaria—Metformin—polycystic ovary syndrome	0.000756	0.00911	CcSEcCtD
Arformoterol—Abdominal pain—Metformin—polycystic ovary syndrome	0.000752	0.00907	CcSEcCtD
Arformoterol—Dobutamine—ADRB2—polycystic ovary syndrome	0.000729	0.0598	CrCbGaD
Arformoterol—Asthenia—Metformin—polycystic ovary syndrome	0.000683	0.00823	CcSEcCtD
Arformoterol—Pruritus—Metformin—polycystic ovary syndrome	0.000673	0.00812	CcSEcCtD
Arformoterol—Diarrhoea—Metformin—polycystic ovary syndrome	0.000651	0.00785	CcSEcCtD
Arformoterol—Dizziness—Metformin—polycystic ovary syndrome	0.000629	0.00758	CcSEcCtD
Arformoterol—Vomiting—Metformin—polycystic ovary syndrome	0.000605	0.00729	CcSEcCtD
Arformoterol—Rash—Metformin—polycystic ovary syndrome	0.0006	0.00723	CcSEcCtD
Arformoterol—Dermatitis—Metformin—polycystic ovary syndrome	0.000599	0.00723	CcSEcCtD
Arformoterol—Headache—Metformin—polycystic ovary syndrome	0.000596	0.00719	CcSEcCtD
Arformoterol—Nausea—Metformin—polycystic ovary syndrome	0.000565	0.00681	CcSEcCtD
Arformoterol—Labetalol—ADRB2—polycystic ovary syndrome	0.000562	0.0461	CrCbGaD
Arformoterol—Isoprenaline—ADRB2—polycystic ovary syndrome	0.000414	0.0339	CrCbGaD
Arformoterol—Isoprenaline—CYP1A1—polycystic ovary syndrome	0.000355	0.0291	CrCbGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	6.5e-05	0.000437	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	6.48e-05	0.000436	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—SRD5A1—polycystic ovary syndrome	6.42e-05	0.000432	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	6.35e-05	0.000427	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	6.34e-05	0.000427	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	6.3e-05	0.000424	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NMNAT3—polycystic ovary syndrome	6.27e-05	0.000422	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—LPCAT2—polycystic ovary syndrome	6.23e-05	0.000419	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—SUOX—polycystic ovary syndrome	6.23e-05	0.000419	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NMNAT3—polycystic ovary syndrome	6.21e-05	0.000418	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	6.17e-05	0.000415	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	6.15e-05	0.000414	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—INHBB—polycystic ovary syndrome	6.14e-05	0.000413	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—STAR—polycystic ovary syndrome	6.12e-05	0.000412	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—INHBB—polycystic ovary syndrome	6.01e-05	0.000404	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	5.93e-05	0.000399	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ISYNA1—polycystic ovary syndrome	5.79e-05	0.00039	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	5.79e-05	0.00039	CbGpPWpGaD
Arformoterol—CYP2C19—Biological oxidations—POMC—polycystic ovary syndrome	5.78e-05	0.000389	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PDE3B—polycystic ovary syndrome	5.74e-05	0.000386	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—SUOX—polycystic ovary syndrome	5.73e-05	0.000386	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—LPCAT2—polycystic ovary syndrome	5.73e-05	0.000386	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—SUOX—polycystic ovary syndrome	5.68e-05	0.000382	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—LPCAT2—polycystic ovary syndrome	5.68e-05	0.000382	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	5.66e-05	0.000381	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PDE3B—polycystic ovary syndrome	5.61e-05	0.000378	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	5.61e-05	0.000377	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	5.59e-05	0.000376	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	5.47e-05	0.000368	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—HMMR—polycystic ovary syndrome	5.46e-05	0.000367	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ISYNA1—polycystic ovary syndrome	5.33e-05	0.000359	CbGpPWpGaD
Arformoterol—CYP2D6—Biological oxidations—POMC—polycystic ovary syndrome	5.31e-05	0.000357	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	5.29e-05	0.000356	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ISYNA1—polycystic ovary syndrome	5.28e-05	0.000355	CbGpPWpGaD
Arformoterol—CYP2C9—Biological oxidations—POMC—polycystic ovary syndrome	5.27e-05	0.000354	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FSHR—polycystic ovary syndrome	5.22e-05	0.000351	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—HSD3B1—polycystic ovary syndrome	5.21e-05	0.00035	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	5.16e-05	0.000347	CbGpPWpGaD
Arformoterol—ADRB1—GPCR ligand binding—POMC—polycystic ovary syndrome	5.11e-05	0.000344	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FSHR—polycystic ovary syndrome	5.11e-05	0.000344	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—GHRL—polycystic ovary syndrome	5.08e-05	0.000342	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	5.02e-05	0.000337	CbGpPWpGaD
Arformoterol—ADRB2—GPCR ligand binding—POMC—polycystic ovary syndrome	5e-05	0.000337	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—GHRL—polycystic ovary syndrome	4.97e-05	0.000334	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—AKR1C2—polycystic ovary syndrome	4.93e-05	0.000331	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—TEAD2—polycystic ovary syndrome	4.93e-05	0.000331	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	4.91e-05	0.00033	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	4.82e-05	0.000324	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	4.8e-05	0.000323	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	4.78e-05	0.000321	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—LHB—polycystic ovary syndrome	4.75e-05	0.000319	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	4.74e-05	0.000319	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	4.67e-05	0.000314	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	4.66e-05	0.000314	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FST—polycystic ovary syndrome	4.66e-05	0.000313	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—HSD3B2—polycystic ovary syndrome	4.64e-05	0.000312	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	4.63e-05	0.000312	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ADRB3—polycystic ovary syndrome	4.6e-05	0.000309	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	4.57e-05	0.000308	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FST—polycystic ovary syndrome	4.55e-05	0.000306	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—LHB—polycystic ovary syndrome	4.54e-05	0.000306	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—AKR1C2—polycystic ovary syndrome	4.53e-05	0.000305	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—TEAD2—polycystic ovary syndrome	4.53e-05	0.000305	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ADRB3—polycystic ovary syndrome	4.5e-05	0.000303	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—AKR1C1—polycystic ovary syndrome	4.49e-05	0.000302	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—AKR1C2—polycystic ovary syndrome	4.49e-05	0.000302	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—TEAD2—polycystic ovary syndrome	4.49e-05	0.000302	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—LHB—polycystic ovary syndrome	4.45e-05	0.000299	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—GNRH1—polycystic ovary syndrome	4.44e-05	0.000299	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—GNRH1—polycystic ovary syndrome	4.34e-05	0.000292	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	4.32e-05	0.000291	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	4.3e-05	0.000289	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	4.29e-05	0.000289	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SCT—polycystic ovary syndrome	4.26e-05	0.000287	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	4.25e-05	0.000286	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	4.21e-05	0.000283	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	4.2e-05	0.000283	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	4.2e-05	0.000283	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SCT—polycystic ovary syndrome	4.17e-05	0.00028	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—SULT2A1—polycystic ovary syndrome	4.14e-05	0.000278	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PNPLA2—polycystic ovary syndrome	4.13e-05	0.000278	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	4.06e-05	0.000273	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—RRM2—polycystic ovary syndrome	4.01e-05	0.00027	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FGF18—polycystic ovary syndrome	3.99e-05	0.000269	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	3.97e-05	0.000267	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—RBP4—polycystic ovary syndrome	3.96e-05	0.000266	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—SRD5A1—polycystic ovary syndrome	3.91e-05	0.000263	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FGF18—polycystic ovary syndrome	3.91e-05	0.000263	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—GNAS—polycystic ovary syndrome	3.9e-05	0.000262	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—RBP4—polycystic ovary syndrome	3.87e-05	0.000261	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—YAP1—polycystic ovary syndrome	3.86e-05	0.00026	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—GNAS—polycystic ovary syndrome	3.81e-05	0.000257	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PNPLA2—polycystic ovary syndrome	3.8e-05	0.000255	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PNPLA2—polycystic ovary syndrome	3.76e-05	0.000253	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—STAR—polycystic ovary syndrome	3.73e-05	0.000251	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—NAMPT—polycystic ovary syndrome	3.71e-05	0.00025	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—YAP1—polycystic ovary syndrome	3.7e-05	0.000249	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	3.69e-05	0.000248	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CYP11A1—polycystic ovary syndrome	3.66e-05	0.000247	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—GAB1—polycystic ovary syndrome	3.65e-05	0.000245	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—YAP1—polycystic ovary syndrome	3.62e-05	0.000243	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—SRD5A1—polycystic ovary syndrome	3.6e-05	0.000242	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—SRD5A1—polycystic ovary syndrome	3.57e-05	0.00024	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—GAB1—polycystic ovary syndrome	3.57e-05	0.00024	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—INSR—polycystic ovary syndrome	3.49e-05	0.000235	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—AKR1C3—polycystic ovary syndrome	3.46e-05	0.000233	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—STAR—polycystic ovary syndrome	3.43e-05	0.000231	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—INSR—polycystic ovary syndrome	3.41e-05	0.000229	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CYP17A1—polycystic ovary syndrome	3.41e-05	0.000229	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—STAR—polycystic ovary syndrome	3.4e-05	0.000229	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	3.36e-05	0.000226	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—HMMR—polycystic ovary syndrome	3.33e-05	0.000224	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	3.31e-05	0.000223	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	3.26e-05	0.000219	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	3.24e-05	0.000218	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PGR—polycystic ovary syndrome	3.23e-05	0.000217	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	3.19e-05	0.000215	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—HSD3B1—polycystic ovary syndrome	3.17e-05	0.000214	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PGR—polycystic ovary syndrome	3.16e-05	0.000212	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	3.14e-05	0.000211	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—HMMR—polycystic ovary syndrome	3.06e-05	0.000206	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—HMMR—polycystic ovary syndrome	3.03e-05	0.000204	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PLAT—polycystic ovary syndrome	3e-05	0.000202	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—GHRL—polycystic ovary syndrome	3e-05	0.000202	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	2.97e-05	0.0002	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—TH—polycystic ovary syndrome	2.95e-05	0.000198	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—GHRL—polycystic ovary syndrome	2.93e-05	0.000197	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PLAT—polycystic ovary syndrome	2.93e-05	0.000197	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	2.92e-05	0.000196	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—LHB—polycystic ovary syndrome	2.89e-05	0.000195	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—HSD3B1—polycystic ovary syndrome	2.89e-05	0.000195	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—POMC—polycystic ovary syndrome	2.89e-05	0.000194	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—SLC2A4—polycystic ovary syndrome	2.87e-05	0.000193	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ATF1—polycystic ovary syndrome	2.86e-05	0.000193	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	2.86e-05	0.000193	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—HSD3B2—polycystic ovary syndrome	2.83e-05	0.00019	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—POMC—polycystic ovary syndrome	2.83e-05	0.00019	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ATF1—polycystic ovary syndrome	2.8e-05	0.000188	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.79e-05	0.000188	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	2.78e-05	0.000187	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—AKR1C1—polycystic ovary syndrome	2.74e-05	0.000184	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.73e-05	0.000184	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	2.72e-05	0.000183	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	2.71e-05	0.000182	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CYP19A1—polycystic ovary syndrome	2.7e-05	0.000181	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	2.66e-05	0.000179	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NGFR—polycystic ovary syndrome	2.64e-05	0.000178	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—LHB—polycystic ovary syndrome	2.64e-05	0.000178	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—POMC—polycystic ovary syndrome	2.62e-05	0.000177	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PRL—polycystic ovary syndrome	2.62e-05	0.000176	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	2.6e-05	0.000175	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NGFR—polycystic ovary syndrome	2.58e-05	0.000174	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—HSD3B2—polycystic ovary syndrome	2.58e-05	0.000174	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—POMC—polycystic ovary syndrome	2.57e-05	0.000173	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PRL—polycystic ovary syndrome	2.56e-05	0.000172	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.52e-05	0.00017	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—SULT2A1—polycystic ovary syndrome	2.52e-05	0.00017	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	2.52e-05	0.00017	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	2.5e-05	0.000168	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.48e-05	0.000167	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.47e-05	0.000166	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—RRM2—polycystic ovary syndrome	2.44e-05	0.000164	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GNAS—polycystic ovary syndrome	2.41e-05	0.000162	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—YAP1—polycystic ovary syndrome	2.35e-05	0.000158	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	2.32e-05	0.000156	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—GNAS—polycystic ovary syndrome	2.3e-05	0.000155	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	2.3e-05	0.000155	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—NCOR1—polycystic ovary syndrome	2.29e-05	0.000154	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NAMPT—polycystic ovary syndrome	2.26e-05	0.000152	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—GNAS—polycystic ovary syndrome	2.25e-05	0.000152	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	2.25e-05	0.000151	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	2.25e-05	0.000151	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	2.23e-05	0.00015	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	2.23e-05	0.00015	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.22e-05	0.000149	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.19e-05	0.000148	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CYP1A1—polycystic ovary syndrome	2.17e-05	0.000146	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	2.17e-05	0.000146	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NRG1—polycystic ovary syndrome	2.15e-05	0.000145	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	2.15e-05	0.000144	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.15e-05	0.000144	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	2.11e-05	0.000142	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NRG1—polycystic ovary syndrome	2.11e-05	0.000142	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	2.08e-05	0.00014	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	2.08e-05	0.00014	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	2.06e-05	0.000139	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	2.05e-05	0.000138	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	2.05e-05	0.000138	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	2.04e-05	0.000137	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—MTHFR—polycystic ovary syndrome	2.03e-05	0.000136	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.02e-05	0.000136	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	1.94e-05	0.000131	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	1.92e-05	0.000129	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	1.91e-05	0.000129	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	1.89e-05	0.000127	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IRS2—polycystic ovary syndrome	1.84e-05	0.000124	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—LEP—polycystic ovary syndrome	1.8e-05	0.000121	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IRS2—polycystic ovary syndrome	1.8e-05	0.000121	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—TH—polycystic ovary syndrome	1.8e-05	0.000121	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—LEP—polycystic ovary syndrome	1.77e-05	0.000119	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	1.75e-05	0.000118	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—TH—polycystic ovary syndrome	1.65e-05	0.000111	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	1.64e-05	0.000111	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PPARG—polycystic ovary syndrome	1.64e-05	0.000111	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—TH—polycystic ovary syndrome	1.64e-05	0.00011	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—POMC—polycystic ovary syndrome	1.62e-05	0.000109	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—INS—polycystic ovary syndrome	1.61e-05	0.000108	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IRS1—polycystic ovary syndrome	1.61e-05	0.000108	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	1.61e-05	0.000108	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	1.59e-05	0.000107	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IRS1—polycystic ovary syndrome	1.58e-05	0.000106	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—POMC—polycystic ovary syndrome	1.55e-05	0.000104	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—INS—polycystic ovary syndrome	1.54e-05	0.000104	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—POMC—polycystic ovary syndrome	1.52e-05	0.000102	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	1.51e-05	0.000102	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—INS—polycystic ovary syndrome	1.51e-05	0.000101	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	1.5e-05	0.000101	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IGF1—polycystic ovary syndrome	1.49e-05	0.0001	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AKT2—polycystic ovary syndrome	1.49e-05	0.0001	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	1.47e-05	9.87e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IGF1—polycystic ovary syndrome	1.46e-05	9.82e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AKT2—polycystic ovary syndrome	1.46e-05	9.81e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.42e-05	9.53e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	1.4e-05	9.4e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.39e-05	9.32e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	1.35e-05	9.08e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	1.34e-05	9e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	1.32e-05	8.91e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	1.29e-05	8.65e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	1.27e-05	8.57e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	1.23e-05	8.31e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	1.22e-05	8.2e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	1.21e-05	8.13e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.14e-05	7.67e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	1.14e-05	7.64e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	1.13e-05	7.58e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.12e-05	7.51e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	1e-05	6.74e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	9.88e-06	6.65e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—INS—polycystic ovary syndrome	9.82e-06	6.61e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.74e-06	6.55e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.53e-06	6.41e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	9.21e-06	6.2e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	9.13e-06	6.14e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	9.08e-06	6.11e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—INS—polycystic ovary syndrome	9.03e-06	6.08e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	9.01e-06	6.06e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—INS—polycystic ovary syndrome	8.96e-06	6.03e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL6—polycystic ovary syndrome	6.74e-06	4.53e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL6—polycystic ovary syndrome	6.59e-06	4.43e-05	CbGpPWpGaD
